Moderna (MRNA) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.38
- Estimate
- -$1.25
- Surprise
- +130.3%
- Revenue (period 2026-09-30)
- $1.31B
- Score today
- 4.0/10
Revenue source: xbrl.
How the report landed
Moderna (MRNA) beat the -$1.25 estimate with adjusted EPS of $0.38 — a large 130.3% upside surprise.
Coverage in the report window
- Moderna Stuns Wall Street With Surprise Profit, Raises Outlook — benzinga, 2026-11-06
- Moderna, JFrog, TransMedics, Ubiquiti And Other Big Stocks Moving Higher On Friday — benzinga, 2026-11-06
- Moderna Q3 2026 Earnings Call Transcript — benzinga, 2026-11-06
Where TrendMatrix's rating stands now
TrendMatrix currently rates MRNA Sell at 4.0/10; no pre/post engine snapshot brackets this report.
4 of the last 4 quarters beat the estimate; this quarter's +130.3% surprise compares with a +41.8% four-quarter average.
What argues against it
- Target reached (-51.0% upside)
- Quality below floor (3.4 < 4.0)
- Negative risk/reward — downside exceeds upside
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $254.19
- Stop
- $236.40
Model outputs from TrendMatrix’s engine as of 2026-11-07 — shown for context, not personalized investment advice.
MRNA at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $101.48B
- P/E (fwd)
- -56.2
- 52-week range
- $22.28–$267.50
- Off 52-week high
- 5.0%
- RSI (14)
- 59
- Volume vs avg
- 0.98×
- Score today
- 4.0/10